Evidence map›Paper›PMID 26917944›Full record

ReviewBiomarker insights2015

Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs.

Gabriele Grunig, Aram Baghdassarian, Sung-Hyun Park, Serhiy Pylawka, Bertram Bleck, Joan Reibman, Erika Berman-Rosenzweig, Nedim Durmus

Abstract readReview
In one paragraph

Review in Biomarker insights, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Overuse of inhaled corticosteroids in COPD: five questions for withdrawal in daily practice.International journal of chronic obstructive pulmonary disease · 2018
    Review
  3. Imaging Pulmonary Inflammation.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gabriele GrunigDepartment of Environmental Medicine, New York University School of Medicine, New York, NY, USA.; Department of Medicine, New York University School of Medicine, New York, NY, USA.
Aram BaghdassarianDepartment of Environmental Medicine, New York University School of Medicine, New York, NY, USA.
Sung-Hyun ParkDepartment of Environmental Medicine, New York University School of Medicine, New York, NY, USA.
Serhiy PylawkaCollege of Dental Medicine, Columbia University, New York, NY, USA.
Bertram BleckDepartment of Medicine, New York University School of Medicine, New York, NY, USA.
Joan ReibmanDepartment of Medicine, New York University School of Medicine, New York, NY, USA.
Erika Berman-RosenzweigDepartment of Pediatrics, School of Medicine, Columbia University, New York, NY, USA.
Nedim DurmusDepartment of Environmental Medicine, New York University School of Medicine, New York, NY, USA.

Funding

T helper 2 Inflammation & Severe Muscularization of Arteries in the Lungs.R01HL095764 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GRUNIG, GABRIELE · 2010 to 2014
$2.0M
PVDOMICS Defining the Future Fingerprints of Pulmonary Vascular DiseaseU01HL125218 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BERMAN-ROSENZWEIG, ERIKA S., HORN, EVELYN · 2014 to 2018
$1.6M
miR-135a and miR-204 in Pulmonary Hypertension induced by antigen and urban air pollutionR03ES024797 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PARK, SUNG HYUN · 2015 to 2016
$170k
NHLBI NIH HHS R01 HL095764NHLBI NIH HHS U01 HL125218NIEHS NIH HHS R03 ES024797
6 · The paper itself

Abstract

This review discusses biomarkers that are being researched for their usefulness to phenotype chronic inflammatory lung diseases that cause remodeling of the lung's architecture. The review focuses on asthma, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension. Bio-markers of environmental exposure and specific classes of biomarkers (noncoding RNA, metabolism, vitamin, coagulation, and microbiome related) are also discussed. Examples of biomarkers that are in clinical use, biomarkers that are under development, and biomarkers that are still in the research phase are discussed. We chose to present examples of the research in biomarker development by diseases, because asthma, COPD, and pulmonary hypertension are distinct entities, although they clearly share processes of inflammation and remodeling.

Indexed as

asthmaCOPDdiagnosisendotypes of diseaselung inflammationlung remodelingpulmonary hypertension

Identifiers

PMID26917944
PMCPMC4756863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.